Posted by Michael Wonder on 05 Aug 2021
MT-3921 granted FDA fast track designation for treatment of spinal cord injury
4 August 2021 - Mitsubishi Tanabe Pharma announced today that Mitsubishi Tanabe Pharma Development America has received fast track designation for MT-3921 from the U.S. FDA for the treatment of spinal cord injury.
MT-3921 is a novel humanised immunoglobulin G1 monoclonal antibody that binds to repulsive guidance molecule A for the treatment of spinal cord injury.
